Single nucleotide polymorphisms of IGFBP-3 gene and lung cancer risk in a Korean population

Lung Cancer

Volumn 62, Issue 2, 2008, Pages 152-161

  Han, Sle Gi Lo ^a   Park, Kyong Hwa ^b   Sung, Jae Sook ^a,b   Whang, Young Mi ^a,b   Kim, Yeon Jung ^c   Shin, Eun Soon ^d   Lee, Jae Won ^e   Lee, Hyo Jung ^e   Ryu, Jeong Seon ^f   Choi, In Keun ^b   Seo, Jae Hong ^b   Kim, Yeul Hong ^a,b  

^a College of Medicine   (South Korea)

^b Korea University Ansan Hospital   (South Korea)

^c Korea National Institute of Health   (South Korea)

^d DNA Link Inc   (South Korea)

^e Korea University   (South Korea)

^f Inha University School of Medicine   (South Korea)

Author keywords

IGFBP 3; Lung cancer; SNP

Indexed keywords

DNA FRAGMENT; SOMATOMEDIN; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ADULT; ARTICLE; BLOOD SAMPLING; CANCER CELL CULTURE; CANCER PATIENT; CANCER RISK; CANCER SUSCEPTIBILITY; CIGARETTE SMOKING; CONTROLLED STUDY; FEMALE; GENE; GENE FREQUENCY; GENE IDENTIFICATION; GENE LOCUS; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SCREENING; GENETIC TRANSCRIPTION; GENOTYPE; HAPLOTYPE; HUMAN; IGFBP 3 GENE; KOREA; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BLOOD LEVEL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM;

ASIAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; INSULIN-LIKE GROWTH FACTOR I; LUNG NEOPLASMS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; RISK FACTORS;

EID: 55049085653     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2008.03.017     Document Type: Article

References (41)

1. Pollak M.N., Schernhammer E.S., and Hankinson S.E. Insulin-like growth factors and neoplasia. Nat Rev Cancer 4 (2004) 505-518
2. London S.J., Yuan J.M., Travlos G.S., Gao Y.T., Wilson R.E., Ross R.K., et al. Insulin-like growth factor I, IGF-binding protein 3, and lung cancer risk in a prospective study of men in China. J Natl Cancer Inst 94 (2002) 749-754
3. Ma J., Pollak M.N., Giovannucci E., Chan J.M., Tao Y., Hennekens C.H., et al. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst 91 (1999) 620-625
4. Platz E.A., Pollak M.N., Leitzmann M.F., Stampfer M.J., Willett W.C., and Giovannucci E. Plasma insulin-like growth factor-1 and binding protein-3 and subsequent risk of prostate cancer in the PSA era. Cancer Causes Control 16 (2005) 255-262
5. Schernhammer E.S., Holly J.M., Hunter D.J., Pollak M.N., and Hankinson S.E. Insulin-like growth factor-I, its binding proteins (IGFBP-1 and IGFBP-3), and growth hormone and breast cancer risk in The Nurses Health Study II. Endocr Relat Cancer 13 (2006) 583-592
6. Schernhammer E.S., Holly J.M., Pollak M.N., and Hankinson S.E. Circulating levels of insulin-like growth factors, their binding proteins, and breast cancer risk. Cancer Epidemiol Biomark Prev 14 (2005) 699-704
7. Wei E.K., Ma J., Pollak M.N., Rifai N., Fuchs C.S., Hankinson S.E., et al. A prospective study of C-peptide, insulin-like growth factor-I, insulin-like growth factor binding protein-1, and the risk of colorectal cancer in women. Cancer Epidemiol Biomark Prev 14 (2005) 850-855
8. Clemmons D.R., Busby W.H., Arai T., Nam T.J., Clarke J.B., Jones J.I., et al. Role of insulin-like growth factor binding proteins in the control of IGF actions. Prog Growth Factor Res 6 (1995) 357-366
9. Renehan A.G., Zwahlen M., Minder C., O'Dwyer S.T., Shalet S.M., and Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 363 (2004) 1346-1353
10. Aishima S., Basaki Y., Oda Y., Kuroda Y., Nishihara Y., Taguchi K., et al. High expression of insulin-like growth factor binding protein-3 is correlated with lower portal invasion and better prognosis in human hepatocellular carcinoma. Cancer Sci 97 (2006) 1182-1190
11. Lee H.Y., Chun K.H., Liu B., Wiehle S.A., Cristiano R.J., Hong W.K., et al. Insulin-like growth factor binding protein-3 inhibits the growth of non-small cell lung cancer. Cancer Res 62 (2002) 3530-3537
12. Oh S.H., Lee O.H., Schroeder C.P., Oh Y.W., Ke S., Cha H.J., et al. Antimetastatic activity of insulin-like growth factor binding protein-3 in lung cancer is mediated by insulin-like growth factor-independent urokinase-type plasminogen activator inhibition. Mol Cancer Ther 5 (2006) 2685-2695
13. Peng L., Wang J., Malloy P.J., and Feldman D. The role of insulin-like growth factor binding protein-3 in the growth inhibitory actions of androgens in LNCaP human prostate cancer cells. Int J Cancer 122 (2008) 558-566
14. Torng PL, Lee YC, Huang CY, Ye JH, Lin YS, Chu YW, et al. Insulin-like growth factor binding protein-3 (IGFBP-3) acts as an invasion-metastasis suppressor in ovarian endometrioid carcinoma. Oncogene 2007; October 22 [Epub ahead of print].
15. Lee K.W., Ma L., Yan X., Liu B., Zhang X.K., and Cohen P. Rapid apoptosis induction by IGFBP-3 involves an insulin-like growth factor-independent nucleomitochondrial translocation of RXRalpha/Nur77. J Biol Chem 280 (2005) 16942-16948
16. Weinzimer S.A., Gibson T.B., Collett-Solberg P.F., Khare A., Liu B., and Cohen P. Transferrin is an insulin-like growth factor-binding protein-3 binding protein. J Clin Endocrinol Metab 86 (2001) 1806-1813
17. Kaaks R., Toniolo P., Akhmedkhanov A., Lukanova A., Biessy C., Dechaud H., et al. Serum C-peptide, insulin-like growth factor (IGF)-I, IGF-binding proteins, and colorectal cancer risk in women. J Natl Cancer Inst 92 (2000) 1592-1600
18. Allen N.E., Roddam A.W., Allen D.S., Fentiman I.S., Dos Santos Silva I., Peto J., et al. A prospective study of serum insulin-like growth factor-I (IGF-I), IGF-II, IGF-binding protein-3 and breast cancer risk. Br J Cancer 92 (2005) 1283-1287
19. Al-Zahrani A., Sandhu M.S., Luben R.N., Thompson D., Baynes C., Pooley K.A., et al. IGF1 and IGFBP3 tagging polymorphisms are associated with circulating levels of IGF1, IGFBP3 and risk of breast cancer. Hum Mol Genet 15 (2006) 1-10
20. Baglietto L., English D.R., Hopper J.L., Morris H.A., Tilley W.D., and Giles G.G. Circulating insulin-like growth factor-I and binding protein-3 and the risk of breast cancer. Cancer Epidemiol Biomark Prev 16 (2007) 763-768
21. Hankinson S.E., Willett W.C., Colditz G.A., Hunter D.J., Michaud D.S., Deroo B., et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 351 (1998) 1393-1396
22. Spitz M.R., Barnett M.J., Goodman G.E., Thornquist M.D., Wu X., and Pollak M. Serum insulin-like growth factor (IGF) and IGF-binding protein levels and risk of lung cancer: a case-control study nested in the beta-carotene and retinol efficacy trial cohort. Cancer Epidemiol Biomark Prev 11 (2002) 1413-1418
23. Wakai K., Ito Y., Suzuki K., Tamakoshi A., Seki N., Ando M., et al. Serum insulin-like growth factors, insulin-like growth factor-binding protein-3, and risk of lung cancer death: a case-control study nested in the Japan Collaborative Cohort (JACC) Study. Jpn J Cancer Res 93 (2002) 1279-1286
24. Wu X., Yu H., Amos C.I., Hong W.K., and Spitz M.R. Joint effect of insulin-like growth factors and mutagen sensitivity in lung cancer risk. J Natl Cancer Inst 92 (2000) 737-743
25. Yu H., Spitz M.R., Mistry J., Gu J., Hong W.K., and Wu X. Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis. J Natl Cancer Inst 91 (1999) 151-156
26. Han J.Y., Choi B.G., Choi J.Y., Lee S.Y., and Ju S.Y. The prognostic significance of pretreatment plasma levels of insulin-like growth factor (IGF)-1, IGF-2, and IGF binding protein-3 in patients with advanced non-small cell lung cancer. Lung Cancer 54 (2006) 227-234
27. Canzian F., McKay J.D., Cleveland R.J., Dossus L., Biessy C., Rinaldi S., et al. Polymorphisms of genes coding for insulin-like growth factor 1 and its major binding proteins, circulating levels of IGF-I and IGFBP-3 and breast cancer risk: results from the EPIC study. Br J Cancer 94 (2006) 299-307
28. Hernandez W., Grenade C., Santos E.R., Bonilla C., Ahaghotu C., and Kittles R.A. IGF-1 and IGFBP-3 gene variants influence on serum levels and prostate cancer risk in African-Americans. Carcinogenesis 28 (2007) 2154-2159
29. Morimoto L.M., Newcomb P.A., White E., Bigler J., and Potter J.D. Variation in plasma insulin-like growth factor-1 and insulin-like growth factor binding protein-3: genetic factors. Cancer Epidemiol Biomark Prev 14 (2005) 1394-1401
30. Chang Y.S., Wang L., Suh Y.A., Mao L., Karpen S.J., Khuri F.R., et al. Mechanisms underlying lack of insulin-like growth factor-binding protein-3 expression in non-small-cell lung cancer. Oncogene 23 (2004) 6569-6580
31. Paquette J., Bessette B., Ledru E., and Deal C. Identification of upstream stimulatory factor binding sites in the human IGFBP3 promoter and potential implication of adjacent single-nucleotide polymorphisms and responsiveness to insulin. Endocrinology 148 (2007) 6007-6018
32. Moon J.W., Chang Y.S., Ahn C.W., Yoo K.N., Shin J.H., Kong J.H., et al. Promoter -202 A/C polymorphism of insulin-like growth factor binding protein-3 gene and non-small cell lung cancer risk. Int J Cancer 118 (2006) 353-356
33. Park K.H., Lo Han S.G., Whang Y.M., Lee H.J., Yoo Y.D., Lee J.W., et al. Single nucleotide polymorphisms of the TGFB1 gene and lung cancer risk in a Korean population. Cancer Genet Cytogenet 169 (2006) 39-44
34. Barrett J.C., Fry B., Maller J., and Daly M.J. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21 (2005) 263-265
35. Chen C., Freeman R., Voigt L.F., Fitzpatrick A., Plymate S.R., and Weiss N.S. Prostate cancer risk in relation to selected genetic polymorphisms in insulin-like growth factor-I, insulin-like growth factor binding protein-3, and insulin-like growth factor-I receptor. Cancer Epidemiol Biomark Prev 15 (2006) 2461-2466
36. Siahpush S.H., Vaughan T.L., Lampe J.N., Freeman R., Lewis S.K., Odze R.D., et al. Longitudinal study of insulin-like growth factor, insulin-like growth factor binding protein-3, and their polymorphisms: risk of neoplastic progression in Barrett's esophagus. Cancer Epidemiol Biomark Prev 16 (2007) 2387-2395
37. Ahn J., Weinstein S.J., Snyder K., Pollak M.N., Virtamo J., and Albanes D. No association between serum insulin-like growth factor (IGF)-I, IGF-binding protein-3, and lung cancer risk. Cancer Epidemiol Biomark Prev 15 (2006) 2010-2012
38. Deal C., Ma J., Wilkin F., Paquette J., Rozen F., Ge B., et al. Novel promoter polymorphism in insulin-like growth factor-binding protein-3: correlation with serum levels and interaction with known regulators. J Clin Endocrinol Metab 86 (2001) 1274-1280
39. Cheng I., DeLellis Henderson K., Haiman C.A., Kolonel L.N., Henderson B.E., Freedman M.L., et al. Genetic determinants of circulating insulin-like growth factor (IGF)-I, IGF binding protein (BP)-1, and IGFBP-3 levels in a multiethnic population. J Clin Endocrinol Metab. 92 (2007) 3660-3666
40. Harrela M., Koistinen H., Kaprio J., Lehtovirta M., Tuomilehto J., Eriksson J., et al. Genetic and environmental components of interindividual variation in circulating levels of IGF-I, IGF-II, IGFBP-1, and IGFBP-3. J Clin Invest 98 (1996) 2612-2615
41. Schernhammer E.S., Hankinson S.E., Hunter D.J., Blouin M.J., and Pollak M.N. Polymorphic variation at the -202 locus in IGFBP3: influence on serum levels of insulin-like growth factors, interaction with plasma retinol and vitamin D and breast cancer risk. Int J Cancer 107 (2003) 60-64